R3 International Offering New Program for Stem Cell Therapy for Liver Failure in Mexico – Yahoo Finance

R3 International is now offering a new program for stem cell therapy for liver failure in Mexico. The program offers up to 200 million stem cells, with the cost starting at only $8975.

SAN DIEGO, June 29, 2020 /PRNewswire-PRWeb/ -- R3 International is now offering a new program for stem cell therapy for liver failure in Mexico. The program offers up to 200 million stem cells, with the cost starting at only $8975.

Millions of individuals suffer from chronic liver disease, which occurs due to a number of causes such as hepatitis, cirrhosis, metabolic diseases, and other conditions. All too often, conventional therapies fail to provide the desired result.

Stem cell therapy has been shown in several studies to produce beneficial results for liver failure. This includes a study of 43 patients from 2012 in Stem Cells and Translational Medicine noting significant increase in survival rates, along with no adverse events.

In its new program, R3 International uses the same weight based protocol. Each treatment provides up to 50 million stem cells at a time, with the treatment occurring at the stem cell therapy clinic in Tijuana Mexico. To date, hundreds of patients have received stem cell therapy in Mexico with R3 for a variety of conditions. No adverse events have been reported, and outcomes have been sensational for organ failure, arthritis, diabetes, dementia, stroke, stem cells for Lyme disease, Crohns and many more.

In order to receive treatment, patients start with a free phone consultation with the licensed, experienced stem cell doctor from R3 International. After the consult and review of medical records, the doctor provides a treatment recommendation. Then the dedicated patient concierge representative will assist with travel logistics and transportation from San Diego to the clinic is provided.

Simply call (888) 988-0515 to schedule the phone consultation and learn about options for treatment.

SOURCE R3 Stem Cell International

Original post:
R3 International Offering New Program for Stem Cell Therapy for Liver Failure in Mexico - Yahoo Finance

Pembrolizumab Approved for First-Line Treatment of Patients With Colorectal Cancer and Key Mutations – AJMC.com Managed Markets Network

The decision comes almost exactly a month after results from KEYNOTE-177 were presented at the annual meeting of the American Society of Clinical Oncology.

Merck, which makes pembrolizumab, sold as Keytruda, announced the approval in a statement.

The approval covers patients who have microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer and is based on results of KEYNOTE-177, a phase 3 trial of 307 patients that found the programmed cell death-1 (PD-1) inhibitor trimmed the risk of death of disease progression 40% compared with chemotherapy, which is the current standard of care (HR = 0.60, 95% CI: 0.45-0.80, P = .0004).

Results presented at ASCO showed that pembrolizumab doubled progression-free survival in these colorectal cancer patients, from 8.2 months to 16.5 months. Lead study author Thierry Andr MD, of the Sorbonne Universit and Hpital Saint Antoine in Paris, said at the time that the findings would change the standard of care. No medical treatment has shown such an improvement, Andr said.

Discussant Michael Overman, MD, of The University of Texas MD Anderson Cancer Center, agreed and said the tumors treated in the study were particularly good candidates for immunotherapy. From now on, he said, It is critical that we test all colorectal cancer patients for mismatch repair or microsatellite status.

The approval came less than a month after Merck submitted a supplemental Biologics License Application, which was handled through FDAs Real-Time Oncology Review pilot program. According to the Merck statement, the approval was reviewed under Project Orbis, an initiative of the FDA Oncology Center of Excellence that allows for concurrent submission and review of oncology drugs among its international partnersin this case, regulators in Australia, Canada, and Switzerland.

Todays approval has the potential to change the treatment paradigm for the first-line treatment of patients with MSI-H colorectal cancer, based on the important findings from KEYNOTE-177 that showed Keytruda monotherapy demonstrated superior progression-free survival compared to standard of care chemotherapy, Roy Baynes, MD, PhD, senior vice president and head of global clinical development, chief medical officer for Merck Research Laboratories, said in the statement.

At ASCO, Andr trumpeted the value of biomarker-driven research, and Baynes did the same today. Our commitment to pursuing biomarker research continues to help us bring new treatments to patients, he said, particularly for those who have few available options.

Immune-related adverse events can include pneumonitis, colitis, hepatitis, skin reactions, renal dysfunction, and endocrinological abnormalities. Patients taking the PD-1 inhibitor may experience solid organ transplant rejection or complications from stem cell transplant.

Luis A. Diaz, MD, head of the division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center. said in the statement that patients with colorectal cancer and the genetic mutations in the study have historically faced poor outcomes, and until today, chemotherapy-containing regimens were the only FDA-approved first-line treatment options.

About 5% of metastatic colorectal cancer patients have MSI-H/dMMR. Pembrolizumabs effectiveness when this mutation is present is well-recognized, and led to FDAs firsttissue-agnostic approvalin May 2017.

See original here:
Pembrolizumab Approved for First-Line Treatment of Patients With Colorectal Cancer and Key Mutations - AJMC.com Managed Markets Network

Genespire and the San Raffaele Telethon Institute for Gene Therapy announce publication in Nature Biotechnology on enhanced gene editing technique in…

June 30, 2020 07:00 ET | Source: Genespire

Genespire and the San Raffaele Telethon Institute for Gene Therapy announce publication in Nature Biotechnology on enhanced gene editing technique in hematopoietic stem cells

Italy, Milan, 30 June 2020: The San Raffaele Telethon Institute for Gene Therapy (SR-Tiget) and Genespire, a gene therapy company developing transformative therapies for genetic diseases, announce today the publication of data highlighting progress in the development of an improved targeted gene replacement technology in human hematopoietic stem cells (HSCs) in Nature Biotechnology.

The paper, entitled Efficient gene editing of human long-term hematopoietic stem cells validated by clonal tracking, outlines technology developed by Pr. Luigi Naldini and his team at SR-Tiget, which is included in the strategic alliance with Genespire. It shows increased homology directed recombination (HDR) efficiency in HSCs by forcing cell-cycle progression and transiently upregulating components of the HDR machinery. The findings are validated by clonal tracking of the edited HSCs in experimental transplantation models, which shows improved polyclonal engraftment by long-term repopulating HSCs.

People with genetic diseases affecting the hematopoietic lineage may benefit from corrective targeted gene therapy in HSCs. These cells are self renewing and can differentiate into all the cell types of the hematopoietic lineage, therefore providing the potential for a one-time therapy. As compared to standard gene replacement approaches, gene editing corrects the disease-causing mutation in situ, restoring both function and physiological expression control of the affected gene. In principle, this targeted strategy may fulfill the goal of precision medicine at the most stringent genetic level. Its realization in HSCs, however, has been hampered until now by low efficiency of HDR-driven repair, likely because of the quiescent state of the more primitive progenitors. Use of the improved gene editing technology developed by SR-Tiget has been shown to yield a greater percentage of gene-edited HSCs and increased clonality, or the number of modified cells transplanted and engrafted in the recipient. In a clinical setting this should lead to increased hematopoietic cells chimerism in the patient receiving the corrective HSC therapy, and could accelerate the hematopoietic recovery after conditioning and increase the size, long-term stability, and safety of the engineered cell graft.

This approach can be applied to genetic diseases originating in the hematopoietic lineage, including primary immune deficiencies (PIDs), a key area of focus for Genespire. Genespire will continue to work with SR-Tiget and apply this technology to its future pipeline of gene therapies.

Julia Berretta, Chief Executive Officer of Genespire, commented: The focus of Genespires alliance with SR-Tiget is to research and develop novel gene therapies, addressing severe diseases with high unmet medical need. We are pleased with the publication of these data in Nature Biotechnology, which provide valuable insights into this pioneering technology developed by SR-Tiget, and we look forward to our future work with them to translate cutting edge science into transformational therapies.

Professor Luigi Naldini, Director of SR-Tiget and scientific co-founder of Genespire, said Our findings elucidate and overcome two main biological barriers to efficient HDR-mediated gene editing in HSCs, and show by clonal tracking that our enhanced editing protocol preserves their multilineage and self-renewal capacity long term after serial transplant. We look forward to our future work with Genespire to explore its potential in primary immunodeficiencies.

The full publication details are below and can be accesed online here.

Efficient gene editing of human long-term hematopoietic stem cells validated by clonal tracking Samuele Ferrari, Aurelien Jacob, Stefano Beretta, Giulia Unali, Luisa Albano, Valentina Vavassori, Davide Cittaro, Dejan Lazarevic, Chiara Brombin, Federica Cugnata, Anna Kajaste-Rudnitski, Ivan Merelli, Pietro Genovese and Luigi Naldini

Enquiries:

About Genespire

Genespire is a biotechnology company focused on the development of transformative gene therapies for patients affected by genetic diseases, particularly primary immunodeficiencies and inherited metabolic diseases. Based in Milan, Italy, Genespire was founded in March 2020 by the gene therapy pioneer Prof. Luigi Naldini and Dr. Alessio Cantore, Fondazione Telethon and Ospedale San Raffaele. It is a spin-off of SR-Tiget, a world leading cell and gene therapy research institute and is backed by Sofinnova Partners. http://www.genespire.com

About SR-Tiget

Based in Milan, Italy, the San Raffaele-Telethon Institute for Gene Therapy (SR-Tiget) is a joint venture between the Ospedale San Raffaele and Fondazione Telethon. SR-Tiget was established in 1995 to perform research on gene transfer and cell transplantation and translate its results into clinical applications of gene and cell therapies for different genetic diseases. Over the years, the Institute has given a pioneering contribution to the field with relevant discoveries in vector design, gene transfer strategies, stem cell biology, identity and mechanism of action of innate immune cells. SR-Tiget has also established the resources and framework for translating these advances into novel experimental therapies and has implemented several successful gene therapy clinical trials for inherited immunodeficiencies, blood and storage disorders, which have already treated >115 patients and have led through collaboration with industrial partners to the filing and approval of novel advanced gene therapy medicines.

Go here to read the rest:
Genespire and the San Raffaele Telethon Institute for Gene Therapy announce publication in Nature Biotechnology on enhanced gene editing technique in...

Covid-19 outbreak imparts profitable opportunities to Stem Cell Therapy market; demand to remain high post pandemic – Jewish Life News

2014-2029 Report on Global Stem Cell Therapy Market By Player, Region, Type, Application And Sales Channel the new research report adds in kandjmarketresearch.com research reports database. Complete report On Stem Cell Therapy Research Report Spread Across 109 Pages, With Summarizing Top Companies and Stem Cell Therapy with Tables and Figures.

Market Overview

The global Stem Cell Therapy market has been studied by a set of researchers for a defined forecast period of 2014 to 2029. This study has provided insights to the stakeholders in the market landscape. It includes an in-depth analysis of various aspects of the market. These aspects include an overview section, with market segmentation, regional analysis, and competitive outlook of the global Stem Cell Therapy market for the forecast period. All these sections of the report have been analyzed in detail to arrive at accurate and credible conclusion of the future trajectory. This also includes an overview section that mentions the definition, classification, and primary applications of the product/service to provide larger context to the audience to this report.

Market Dynamics

The report on the global Stem Cell Therapy market includes a section that discusses various market dynamics that provide higher insight in the relationship and the impact of change these dynamics hold on the market functioning. These dynamics include the factors that are providing impetus to the market over the forthcoming years for growth and expansion. Alternatively, it also includes factors that are poised to challenge the market growth over the forecast period. These factors are expected to reveal certain hidden trends that aid in the better understanding of the market over the forecast period.

The Final Report Will Include the Impact of COVID 19 Analysis in This Stem Cell Therapy Industry.

Get Free Sample Report on Stem Cell Therapy @: https://www.kandjmarketresearch.com/sample-request/328640

Key Players

The global Stem Cell Therapy market report has provided a profiling of significant players that are impacting the trajectory of the market with their strategies for expansion and retaining of market share.

Leading players of Stem Cell Therapy including:

Market split by Type, can be divided into:

Market split by Application, can be divided into:

Do You Have Any Query or Specific Requirement? Ask to Our Trade Expert @ https://www.kandjmarketresearch.com/enquiry/328640

Market Segmentation

The global Stem Cell Therapy market has been studied for a detailed segmentation that is based on different aspects to provide insight in the functioning of the segmental market. This segmentation has enabled the researchers to study the relationship and impact of the growth chart witnessed by these singular segments on the comprehensive market growth rate. It has also enabled various stakeholders in the global Stem Cell Therapy market to gain insights and make accurate relevant decisions. A regional analysis of the market has been conducted that is studied for the segments of North America, Asia Pacific, Europe, Latin America, and the Middle East & Africa.

Research Methodology

The global Stem Cell Therapy market has been analyzed using Porters Five Force Model to gain precise insight in the true potential of the market growth. Further, a SWOT analysis of the market has aided in the revealing of different opportunities for expansion that are inculcated in the market environment.

Market split by Sales Channel, can be divided into:

Market segment by Region/Country including:

Read More Detailed Information regarding Stem Cell Therapy Industry with Covid-19 Updates @: https://www.kandjmarketresearch.com/reports/328640-2014-2029-report-on-global-stem-cell-therapy-market-by-player-region-type-application-and-sales-channel

About Us:

Kandjmarketresearch.com is part of the KnowledgeNJournals Research Firm which provides premium progressive market research reports, statistical surveying, analysis & forecast data for industries and governments from hundreds of publishers around the world. We have almost all top publishers reports in our collection to provide you with instant online access to the worlds most complete and fresh database on a Daily Basis. We are at KandJ Market Research are inspired to help our clients grow by providing appropriate business insight with our huge market intelligence source.

If you have any special requirements for the report, please let us know and we will offer you a customized report on separate regional or country-level reports.

Contact us:

KandJ Market Research

(Part of KnowledgeNJournals Research)

E-mail: [emailprotected]

Website: https://www.kandjmarketresearch.com

Call us: +1 661 636 6162 | +91 932 580 2062

Go here to read the rest:
Covid-19 outbreak imparts profitable opportunities to Stem Cell Therapy market; demand to remain high post pandemic - Jewish Life News

Research Antibodies Market To Reach USD 5.33 Billion By 2027 | Reports and Data – GlobeNewswire

June 29, 2020 17:00 ET | Source: Reports and Data

New York, June 29, 2020 (GLOBE NEWSWIRE) -- The globalresearch antibodies marketis expected to reach USD 5.33 Billion by 2027, according to a new report by Reports and Data. Rising research activities in the field of stem cells is a significant factor driving the growth of the market. Stem cells have the capability of discerning and regenerating various kinds of cells in the human body. These cells possess the potential to cure life-threatening diseases such as oncological and blood-related disorders. Cord blood stem cells find application in the treatment of more than 80 blood-related ailments, such as Sickle Cell Disease. It is projected that over 27 million babies across the globe are born with some kind of blood disorder. As per the World Health Organization, in 2008, 100,000 children were found to be suffering from thalassemia in India.

Increased funding for research and development activities is instrumental in driving the growth of the market. Investment in the healthcare R&D by the US has witnessed a growth of 18.1% between the years 2014 and 2017. In the year 2017, in the US, the overall expenditure on healthcare R&D was USD 182.30 billion. Besides, according to the 2016 financial statements of Celgene Corporation, a leading biopharmaceutical firm, the R&D expenditure grew by USD 772.8 million (21.0% more than 2015 expenses) in 2016 to USD 4.47 billion. Also, a USD 892.9 million of R&D asset acquisition spending, comprising a USD 625.0 million purchase of Engmab AG, a private firm engaged in T-cell bispecific antibodies, added to the overall R&D expenses of the Celgene.

However, cost-prohibitive research antibodies and issues related to the quality of nontherapeutic antibodies may create hindrances in the growth of the market in the upcoming years.

Get FREE Sample Copy with TOC of the Report to understand the structure of the complete report@ https://www.reportsanddata.com/sample-enquiry-form/3270

COVID-19 Impact As the global economies are experiencing the negative impact of the Covid-19 pandemic, organizations are suffering losses, among various other challenges. Nevertheless, firms in the pharmaceutical industry are of immense importance in combatting the pandemic and are witnessing positive growth in the contagious disease landscape with the race for treatment approval therapy gaining momentum.

In April 2020, the ICMR (Indian Council of Medical Research) announced that it would fast-track funding proposals intended for immunology approaches for the treatment of coronavirus, a step to bridge the research gap in the country to combat the pandemic.

Further key findings from the report suggest

BUY NOW (Customized Report Delivered as per Your Specific Requirement)@ https://www.reportsanddata.com/checkout-form/3270

For the purpose of this report, Reports and Data have segmented the global research antibodies market on the basis of product, antibody type, technology, application, end-users, and region:

ProductOutlook (Revenue, USD Million; 2017-2027)

Antibody TypeOutlook (Revenue, USD Million; 2017-2027)

TechnologyOutlook (Revenue, USD Million; 2017-2027)

ApplicationOutlook (Revenue, USD Million; 2017-2027)

Industry VerticalOutlook (Revenue, USD Million; 2017-2027)

To identify the key trends in the industry, click on the link below: https://www.reportsanddata.com/report-detail/research-antibodies-market

Regional Outlook (Revenue, USD Million; 2017-2027)

Take a Look at our Related Reports:

E-Prescribing Market: https://www.reportsanddata.com/report-detail/e-prescribing-market

Mobile Health (mHealth) Market: https://www.reportsanddata.com/report-detail/mobile-health-mhealth-market

Artificial Intelligence in Drug Discovery Market: https://www.reportsanddata.com/report-detail/artificial-intelligence-in-drug-discovery-market

About Reports and Data

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help clients make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power, and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise.

Visit link:
Research Antibodies Market To Reach USD 5.33 Billion By 2027 | Reports and Data - GlobeNewswire

Benefit From CD19 CAR T-Cell Therapy in Relapsed/Refractory B-Cell ALL – Hematology Advisor

Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy yields a high rate of complete remission (CR) for patients with relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL), including those who have high-risk features, according to a study published in Blood Advances.

The phase 1/2 study (IM19CAR-T; ClinicalTrials.gov Identifier: NCT03173417), conducted at the Lu Daopei Hospital in China, aimed to assess the efficacy and safety of anti-CD19 CAR T cells in patients with R/R B-ALL, including patients with the following high-risk features: extramedullary disease, TP53 mutation, BCR-ABL1+, or relapse after allogeneic hematopoietic stem cell transplantation (allo-HSCT).

The primary endpoints measured short-term efficacy (CR and minimum residual disease [MRD]-negative CR on day 30) and safety (CAR T-cellrelated cytokine release syndrome and neurotoxicity). The secondary endpoints included 1-year overall survival (OS) and leukemia-free survival (LFS) after CAR T-cell therapy.

Of the 115 patients with CD191 B-ALL who were enrolled in the study, 110 participants (62% male) were successfully infused with anti-CD19 CAR T cells. The median patient age was 12 years (range, 2-61 years); however, most patients (71 participants) were between ages 2 and 14 years.

Overall, 93% of patients achieved a morphologic CR. Among these, 87% became MRD-negative at 30 days. Efficacy was observed across all high-risk feature subgroups as well. Among the 110 patients, the 1-year LFS and OS was 58% and 64%, respectively.

A subset of 75 patients (73.5%) received allo-HSCT after CAR T-cell infusion. These patients demonstrated longer LFS (76.9% vs 11.6%; P <.0001) and OS (79.1% vs 32.0%; P <.0001) than those who received CAR T-cell therapy alone, and this was confirmed in a multivariate analysis (hazard ratio [HR], 16.546).

Notably, patients with TP53 mutation had a lower OS (51.9% vs 89.0%; P <.0001 and LFS (42.4% vs 82.6%; P =.0002) than those without TP53 mutation, and this was also confirmed in a multivariate analysis (HR, 0.235).

Age did not significantly affect CR rate, OS, or LFS when comparing patients aged 2 to 14 years with those older than 14 years.

The authors reported mild cytokine release syndrome and neurotoxicity. Cytokine release syndrome occurred in most patients (92%); however, most of these cases (76%) were grade 1 to 2, with a minority (16%) having grade 3 to 4. Overall, neurotoxicity was less common (any grade, 21%; grade 2 to 3, 14%; grade 1, 7%).

The primary limitations of the study were that it was conducted at a single center and the allo-HSCT recipients were not randomly selected.

Despite the high rates of CR, the authors concluded, The relapse rate for subgroups with high-risk features after CAR T-cell treatment alone remains high, and CAR T-cell therapy followed by subsequent consolidative allo-HSCT has showed better LFS and OS in our study. However, the benefit of a subsequent allo-HSCT transplant requires confirmation with randomized allocation.

Disclosures: Some authors have declared affiliations with the pharmaceutical industry. Please refer to the original study for a full list of disclosures.

Zhang X, Lu X, Yang J, et al. Efficacy and safety of anti-CD19 CAR T-cell therapy in 110 patients with B-cell acute lymphoblastic leukemia with high-risk features. Blood Adv. 2020;4(10):2325-2338.

See the original post here:
Benefit From CD19 CAR T-Cell Therapy in Relapsed/Refractory B-Cell ALL - Hematology Advisor

COVID-19: UAE treats 2000 virus patients with novel stem cell therapy – Gulf News

Following an initial trial, researchers concluded that UAECell19 reduced the duration of hospitalisation from 22 days to just six. Image Credit: iStock

Abu Dhab:The Abu Dhabi Stem Cell Centre (ADSCC) has now treated more than 2,000 patients suffering from COVID-19, with 1,200 already fully recovered from the effects of the virus.

ADSCC announced today that it had succeeded in ramping up the number of treatments from 73 in the initial clinical trials. The large increase was a result of a major effort by staff at the centre to treat as many people as possible, following the UAE Governments decision to make it available free of charge to all moderate-to-high risk COVID-19 patients in the country.

The Governments decision came after the treatment, branded UAECell19, demonstrated efficacy and an impressive safety profile was reflected in the absence of significant changes in adverse events reported, absence of any unexpected serious reactions (such as anaphylaxis, allergic reactions or sudden death) and an absence of any lung complications as determined by radiological exams from inhalation of the nebulised product.

A team of doctors and researchers at ADSCC, led by Dr Yendry Ventura, announced in May that they had developed a new treatment for COVID-19 patients. UAECell19, an autologous stem cell-based therapy, appears to help the body fight the virus and makes the virus less harmful.

Following an initial trial, researchers were able to conclude that UAECell19 reduced the duration of hospitalisation from 22 days to just six, when compared to patients who had received standard treatment.

Further analyses revealed that patients treated with the stem cells were 3.1 times more likely to recover in less than seven days than those treated with standard therapy, and 67 per cent of the patients who received stem celltreatment owed this recovery to the new treatment.

ADSCC has since secured intellectual property rights protection for UAECell19, which opens the way for the treatment to be shared widely so more patients can benefit from it.

ADSCC said researchers are at various stages of investigative efforts to establish effectiveness (Phase 3 trial), optimal efficacy of dosageand efficacy to treat other respiratory diseases such asthma, COPDand cystic fibrosis.

Go here to see the original:
COVID-19: UAE treats 2000 virus patients with novel stem cell therapy - Gulf News

Hematopoietic Stem Cells Transplantation (HSCT) Market Key Manufactures And Chance Analysis-Kite Pharma, Thermo Fisher Scientific, CellGenix…

Hematopoietic Stem Cells Transplantation (HSCT) Market report provides (6 Year Forecast 2020-2026) including detailed Coronavirus (COVID-19) impact analysis on Market Size, Regional and Country-Level Market Size, Segmentation Market Growth, Market Share, Competitive Landscape, Sales Analysis and Value Chain Optimization. This Hematopoietic Stem Cells Transplantation (HSCT) market competitive landscape offers details by topmost key manufactures (Kite Pharma, Thermo Fisher Scientific, CellGenix Technologie Transfer, Cesca Therapeutics, R&D Systems) including Company Overview, Company Total Revenue (Financials), Market Potential, Presence, Hematopoietic Stem Cells Transplantation (HSCT) industry Sales and Revenue Generated, Market Share, Price, Production Sites and Facilities, SWOT Analysis, Product Launch. For the period 2014-2020, this study provides the Hematopoietic Stem Cells Transplantation (HSCT) sales, revenue and market share for each player covered in this report.

Key Target Audience of Hematopoietic Stem Cells Transplantation (HSCT) Market: Manufacturers of Hematopoietic Stem Cells Transplantation (HSCT), Raw material suppliers, Market research and consulting firms, Government bodies such as regulating authorities and policy makers, Organizations, forums and alliances related to Hematopoietic Stem Cells Transplantation (HSCT) market.

Get Free Sample PDF (including COVID-19 Impact Analysis, full TOC, Tables and Figures)of Hematopoietic Stem Cells Transplantation (HSCT)[emailprotected]https://www.researchmoz.us/enquiry.php?type=S&repid=2039940

Synopsis of Hematopoietic Stem Cells Transplantation (HSCT) Market:Hematopoietic stem cell transplants (HSCT) present to a valid treatment for several congenital and other hematopoietic system disorders, post chemotherapy, and immune sensitive diseases. HSCT is also preferred for replacement of cellular components and deficient cells. The indications for HSCT thus are wide; the most frequent indication as per reported by Worldwide Network for Blood and Marrow Transplantation Group (WNBT) (2013) is lymphoproliferative disorder (53.2% of all HSCT), 12% of whom received allogeneic and the rest received autologous transplant. Plasma cell disorders are the most frequent indication in this group. A multitude of literature published by researchers and organizations demonstrate that autologous transplant own a greater edge against allogeneic HSCT.

Over 30 years of studies in the field of blood-forming stem cells i.e. hematopoietic stem cells (HSC), researchers have developed significant understanding to use HSCs as a therapy. At present, no type of stem cell, adult, embryonic or fetal has attained such sufficient status. Hematopoietic stem cell transplantation (HSCT) is now routinely used for treating patients with malignant and non-malignant disorders of blood and the immune system. Currently, researchers have observed that through animal studies HSCs have the ability to form other cells such as blood vessels, muscles, and bone. Further application of this approach it may eventually be able to treat a wide array of conditions and replace ailing tissues. However, despite the vast experience with HSCs, researchers face major barriers in expanding their use beyond the replacement of immune and blood cells.

Hematopoietic stem cells are unable to proliferate and differentiate in-vitro. Researchers have yet to evolve an accurate method to differentiate stem cells from other cells derived from blood or bone marrow. Once such technical barriers are overcome, the avenues for realizing the full potential of HSCT. The type of transplant a person receives depends on several different factors, including the type and course of the disease, availability of suitable donors, and the patients overall health. There are three different sources of hematopoietic stem cells such as bone marrow, peripheral blood stem cells, and umbilical cord blood. The stem cell source used for a given transplant depends upon the underlying disease, the type of transplant (allogeneic or autologous), and size of the patient.

Based onProduct Type, Hematopoietic Stem Cells Transplantation (HSCT) market report displays the manufacture, profits, value, and market segment and growth rate of each type, covers:

Autologous Transplant Allogenic Transplant

Based onend users/applications, Hematopoietic Stem Cells Transplantation (HSCT) market report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, this can be divided into:

Leukemia Lymphoproliferative Disorders Solid Tumors Non-Malignant Disorders Others

Hematopoietic Stem Cells Transplantation (HSCT) Market: Regional analysis includes:

Do You Have Any Query Or Specific Requirement? Ask to Our Industry[emailprotected]https://www.researchmoz.us/enquiry.php?type=E&repid=2039940

The Hematopoietic Stem Cells Transplantation (HSCT) Market Report Can Answer The Following Questions:

What are the Upstream Raw Materials And Manufacturing Equipment of Hematopoietic Stem Cells Transplantation (HSCT)? What is the manufacturing process of Hematopoietic Stem Cells Transplantation (HSCT)?

Who are the key manufacturers of Hematopoietic Stem Cells Transplantation (HSCT) market? How are their operating situation (Capacity, Production, Price, Cost, Gross and Revenue)?

Economic impact on Hematopoietic Stem Cells Transplantation (HSCT) industry and development trend of Hematopoietic Stem Cells Transplantation (HSCT) industry.

What is the (North America, South America, Europe, Africa, Middle East, Asia, China, Japan) Production, Production Value, Consumption, Consumption Value, Import And Export of Hematopoietic Stem Cells Transplantation (HSCT)?

What will the Hematopoietic Stem Cells Transplantation (HSCT) Market Size and The Growth Rate be in 2026?

What are the key market trends impacting the growth of the Hematopoietic Stem Cells Transplantation (HSCT) market?

What are the Hematopoietic Stem Cells Transplantation (HSCT) Market Challenges to market growth?

What are the types and applications of Hematopoietic Stem Cells Transplantation (HSCT)? What is the market share of each type and application?

What are the key factors driving the Hematopoietic Stem Cells Transplantation (HSCT) market?

What are the Hematopoietic Stem Cells Transplantation (HSCT) market opportunities and threats faced by the vendors in the Hematopoietic Stem Cells Transplantation (HSCT) market?

Contact:

ResearchMoz Mr. Rohit Bhisey, Tel: +1-518-621-2074 USA-Canada Toll Free: 866-997-4948 Email:[emailprotected]

Browse More Reports Visit @https://www.mytradeinsight.blogspot.com/

More here:
Hematopoietic Stem Cells Transplantation (HSCT) Market Key Manufactures And Chance Analysis-Kite Pharma, Thermo Fisher Scientific, CellGenix...

UAE stem cell therapy treats over 2000 coronavirus patients, 1200 fully recover – Khaleej Times

The Abu Dhabi Stem Cell Centre (ADSCC) has now treated more than 2,000 patients suffering from Covid-19, with 1,200 already fully recovered from the effects of the virus.

ADSCC announced today that it had succeeded in ramping up the number of treatments from 73 in the initial clinical trial.

The large increase was as a result of a major effort by staff at the centre to treat as many people as possible following the UAE Government's decision to make it available free of charge to all moderate-to-high risk Covid-19 patients in the country.

Also read: UAE expects Covid-19 vaccine by end of 2020 or early 2021

The Government's decision came after the treatment, branded UAECell19, demonstrated efficacy and an impressive safety profile reflected in the absence of significant changes in adverse events reported, an absence of any unexpected serious reactions (such as anaphylaxis, allergic reactions or sudden death) and an absence of any lung complications as determined by radiological exams from inhalation of the nebulized product.

A team of doctors and researchers at ADSCC, led by Dr Yendry Ventura, announced in May that they had developed a new treatment for Covid-19 patients. UAECell19, an autologous stem cells based therapy, appears to help the body fight the virus and makes the disease less harmful.

Following an initial trial, researchers were able to conclude that UAECell19 reduced the duration of hospitalisation from 22 days to just six, when compared to patients who had received standard treatment.

Further analyses revealed that patients treated with the stem cells were 3.1 times more likely to recover in less than seven days than those treated with standard therapy, and 67 per cent of the patients who received the stem cells treatment owed this recovery to the new treatment.

ADSCC has since secured intellectual property rights protection for UAECell19, which opens the way for the treatment to be shared widely so more patients can benefit.

ADSCC said researchers are at various stages of several investigatory efforts to establish effectiveness (Phase 3 trial), optimal efficacy of dosage, and efficacy to treat other respiratory diseases such asthma, COPD, and cystic fibrosis.

Here is the original post:
UAE stem cell therapy treats over 2000 coronavirus patients, 1200 fully recover - Khaleej Times

Innovative treatments that harnesses bodys own immune cells to fight cancer now offered at Jimmy Everest Center – KFOR Oklahoma City

OKLAHOMA CITY (KFOR) An innovative treatment that is harnessing the bodys own immune cells to fight cancer is now being offered at the Jimmy Everest Center for Cancer and Blood Disorders in Children for young people diagnosed with a type of leukemia.

The Jimmy Everest Center, a clinic within OU Childrens Physicians, treats many young people with leukemia.

In the pediatric population, the treatment CAR-T is specifically for young people up to age 25 who have precursor B-cell acute lymphoblastic leukemia (ALL), an aggressive form of blood cancer. To receive CAR-T, their cancer must have returned or become resistant to treatment.

CAR-T is a process in which the patients own cells are redirected to attack the leukemia cells, said David Crawford, M.D., Ph.D., who sees patients in the Jimmy Everest Center. This is a great opportunity because our patients can now be treated with CAR-T at home instead of us sending them to other institutions for the treatment.

CAR-T stands for Chimeric Antigen Receptor T-cell therapy. Patients being treated with CAR-T first have their blood collected in a process similar to a typical blood donation. White blood cells (which include T cells) are filtered out, and the plasma and red cells are returned to the patient. The cells are then sent to a company that inserts the gene for a chimeric antigen receptor into the T cells, which binds to cancer cells and activates the T cells.

This process allows the newly engineered T cells to recognize and attack cancer with remarkable efficiency. Once the CAR-T cells are generated, they are shipped back to the Jimmy Everest Center and given to the patient through an IV, much like a blood transfusion.

Precursor B-cell ALL is the most common childhood malignancy affecting kids from childhood through young adulthood, peaking in diagnoses between ages 3 and 6. Many are cured with chemotherapy and other treatments, but some are not.

Children who relapse are in the greatest danger, Crawford said. For patients who relapse after a stem cell transplant, for example, we previously didnt have any more options. CAR-T is really a game-changer for them.

Unlike other types of cancer therapies, CAR-T therapy is a one-time treatment. The T cells remain in the body, prepared to attack the cancer at any time. The therapy carries a risk of complications, such as cytokine release syndrome and neurotoxicity, but patients are closely monitored and seen daily by their physician, Crawford said.

CAR-T is also being offered at Stephenson Cancer Center for adults diagnosed with advanced lymphomas who are not responding to other treatments. Clinical trials are underway to determine if CAR-T can be used to treat other types of cancer in both adults and children.

For Crawford, it is gratifying to offer his patients and families new hope through CAR-T. Even when his young patients respond well to standard treatment, their quality of life is significantly affected. For those who dont, CAR-T can be a lifesaver.

I wanted to be in a field of medicine where I thought what I was doing made a big difference, and no place can you feel more like that when the patient faces a certainty of dying without the treatment you give them, he said. CAR-T is a breakthrough for our patients.

Latest stories:

OKLAHOMA CITY (KFOR) As state leaders prepare for a public update on the state's coronavirus response, health officials say Oklahomans should still heed the warnings about large groups and take precautions.

On Tuesday morning, data from theOklahoma State Department of Healthshows that the state has had 13,757 confirmed cases of COVID-19 since March.

Read the Full Article

WASHINGTON D.C. (Nexstar) Texas and Oklahoma Republican Senators John Cornyn and Jim Inhofe are trying to shore up the oil industry and oil jobs in their states.

As the pandemic has all but dried-up demand for oil, the senators have introduced a bill that would keep the money flowing to energy companies and keep oil and gas workers on the payroll.

Read the Full Article

CRAIG COUNTY, Okla. (KFOR) - Officials are releasing more information following a deadly trooper-involved shooting last week.

Shortly before 9 a.m. on Thursday, Oklahoma Highway Patrol Trooper Caleb Cole pulled over a vehicle along the Will Rogers Turnpike for a traffic violation.

Read the Full Article

Read more:
Innovative treatments that harnesses bodys own immune cells to fight cancer now offered at Jimmy Everest Center - KFOR Oklahoma City